Reproducibility in Cancer Biology: The who, where and how of fusobacteria and colon cancer
Trillions of microbes live on or in the body of a typical human, and this relationship is mostly harmonious. Our colons harbor the highest density of bacteria, with a mucus barrier protecting our gut from them. For 50 years, scientists have researched who amongst these bacteria might cause colon cancer, where these bacteria might act in the colon, and how they might cause colon cancer.
In 2012 researchers at the BC Cancer Agency, Simon Fraser University and the University of Guelph reported that they had used sequence-based technologies to show that Fusobacterium nucleatum, a species not previously linked to cancer, might be associated with colon cancer (Castellarin et al., 2012). They found that the levels of F. nucleatum in colorectal carcinoma were significantly higher than the levels in adjacent normal tissue. An independent group also reported a similar finding at the same time (Kostic et al., 2012). This was a surprise as F. nucleatum is usually found in the mouth.
In 2016, as part of the Reproducibility Project: Cancer Biology, Repass et al. published a Registered Report which explained in detail how they would seek to replicate the experiment (figure 2 in Castellarin et al.) in which quantitative polymerase chain reaction (qPCR) was used to detect F. nucleatum in colon tissues taken from colon cancer patients (Repass et al., 2016). The results of this experiment have now been published as a Replication Study (Repass and Reproducibility Project: Cancer Biology, 2018). In short, F. nucleatum was detected in just 25% of colorectal carcinomas in the Replication Study, and the difference in the level of this species in colorectal carcinomas and adjacent tissues (there was 10% more F. nucleatum in the carcinomas) was not significant.
So why did the Replication Study not find what was reported in the original study? One possible explanation is that Castellarin et al. studied 99 colon tissue pairs (tumor and tumor-adjacent tissues) from colon cancer patients. The Replication Study, on the other hand, included samples from 40 patients with cancer (both tumor and adjacent tissue), along with 40 non-diseased control tissue samples from age, sex and ethnicity matched individuals. A power calculation had suggested that a sample size of 40 would be big enough to see the effect reported in the original paper, assuming that the two populations were clinically similar. However, Castellarin et al. did not fully report the clinical metadata for their study (such as age, gender, ethnicity and risk factors for disease), so differences between the populations might explain why the original results were not replicated. This possibility is also supported by the fact that the relative abundance of F. nucleatum in tumors in the original experiment is much higher than in the Replication Study.
Technical issues might also have contributed to the lack of replication: in particular, in the Replication Study, qPCR suggested that F. nucleatum DNA was present in 26 samples, albeit at low levels, but qPCR amplicon sequencing detected the presence of specific F. nucleatum gene products in just 16 of these samples (10 in carcinomas; 6 in adjacent tissues). Moreover, all the non-specific amplicons (that is, the 10 that were not due to F. nucleatum) were detected very close to the detection limit of this technique.
Given that numerous studies have already shown that there is an association between F. nucleatum and the microbiota of human colon cancer (see Repass et al., 2016 and Gholizadeh et al., 2017 for reviews), the Replication Study is not a reason to change our view of this association. Rather, it provides a critical opportunity to reflect on our growing, yet incomplete, knowledge regarding fusobacteria and colon cancer. First, and most obvious, there is a need for prospective human studies in well-defined populations – using both microbiology and bioinformatics approaches – to carefully probe how risk factor and other clinical features might alter colon health in the presence of fusobacteria. For example, while F. nucleatum has certainly been the species most consistently identified in association with colon cancer to date, many studies have raised the possibility that other species of fusobacteria, or bacteria that co-aggregate in the presence F. nucleatum, could contribute to the pathogenesis of colon cancer (Castellarin et al., 2012; Kostic et al., 2012; Drewes et al., 2017; Bullman et al., 2017).
Further, while it is clear that fusobacteria are highly genetically diverse (Castellarin et al., 2012; Manson McGuire et al., 2014), we do not as yet understand whether the strains associated with colon cancer exhibit unique genetic features or are related to the fusobacteria that are common in the mouth.
There are also other gaps in our understanding. For example, some experiments that used daily inoculations of F. nucleatum in mouse models of colon cancer suggest that F. nucleatum acts early in colon cancer (Kostic et al., 2013; Yang et al., 2017), whereas germ-free mouse experiments – which are, arguably, a more definitive way to test the role of F. nucleatum on its own in tumor induction – refute this result (Tomkovich et al., 2017). In contrast, at least two studies (Castellarin et al., 2012; Bullman et al., 2017) suggest that F. nucleatum acts late in the tumor process, and research by the present author and co-workers could not discern an association with tumor stage (Drewes et al., 2017).
There is also uncertainty about where F. nucleatum is found: some researchers have reported that it is found with increased frequency in cancers on the right side of the colon (Mima et al., 2016), whereas this effect was not seen in other experiments (Drewes et al., 2017). The question of 'where?' is also complicated by the fact that right colon cancer contains prominent mucus-invasive bacterial biofilms, and about one third of these exhibit blooms of F. nucleatum.
Lastly, we lack a clear picture of how F. nucleatum contributes to the emergence of human colon cancer. Limited data suggest a wide range of putative mechanisms (including Wnt nuclear signaling, immune cell recruitment, checkpoint molecules and specific miRNA induction). While each mechanism is plausible, we lack a cohesive, step-by-step story for F. nucleatum carcinogenesis (Gholizadeh et al., 2017; Kostic et al., 2013; Yang et al., 2017).
While the Replication Study did not replicate the results of Castellarin et al., it provided useful information about the importance of population differences and the need for accurate F. nucleatum detection methods, and highlighted how much we need to learn about the links between F. nucleatum and colon cancer. A better understanding of the who (which Fusobacterium species and/or associates), the where (where in the colon, where in the world) and the how (which disease mechanisms) will help with the development of new prevention approaches, diagnostics and/or therapies for a cancer that is increasing in the young and also across the globe.
Note
Cynthia L Sears was the Reviewing Editor for the Registered Report (Repass et al., 2016) and the Replication Study (Repass and Reproducibility Project: Cancer Biology, 2018).
References
-
Carcinogenesis mechanisms of Fusobacterium nucleatumBiomedicine & Pharmacotherapy 89:918–925.https://doi.org/10.1016/j.biopha.2017.02.102
-
Fusobacterium nucleatum in colorectal carcinoma tissue according to tumor locationClinical and Translational Gastroenterology 7:e200.https://doi.org/10.1038/ctg.2016.53
Article and author information
Author details
Publication history
- Version of Record published: March 13, 2018 (version 1)
Copyright
© 2018, Sears
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 1,949
- Page views
-
- 236
- Downloads
-
- 19
- Citations
Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Cancer Biology
- Computational and Systems Biology
Pancreatic cancer is one of the deadliest cancer types with poor treatment options. Better detection of early symptoms and relevant disease correlations could improve pancreatic cancer prognosis. In this retrospective study, we used symptom and disease codes (ICD-10) from the Danish National Patient Registry (NPR) encompassing 6.9 million patients from 1994 to 2018,, of whom 23,592 were diagnosed with pancreatic cancer. The Danish cancer registry included 18,523 of these patients. To complement and compare the registry diagnosis codes with deeper clinical data, we used a text mining approach to extract symptoms from free text clinical notes in electronic health records (3078 pancreatic cancer patients and 30,780 controls). We used both data sources to generate and compare symptom disease trajectories to uncover temporal patterns of symptoms prior to pancreatic cancer diagnosis for the same patients. We show that the text mining of the clinical notes was able to complement the registry-based symptoms by capturing more symptoms prior to pancreatic cancer diagnosis. For example, ‘Blood pressure reading without diagnosis’, ‘Abnormalities of heartbeat’, and ‘Intestinal obstruction’ were not found for the registry-based analysis. Chaining symptoms together in trajectories identified two groups of patients with lower median survival (<90 days) following the trajectories ‘Cough→Jaundice→Intestinal obstruction’ and ‘Pain→Jaundice→Abnormal results of function studies’. These results provide a comprehensive comparison of the two types of pancreatic cancer symptom trajectories, which in combination can leverage the full potential of the health data and ultimately provide a fuller picture for detection of early risk factors for pancreatic cancer.
-
- Cancer Biology
Cancer stem cells (CSCs) undergo epithelial-mesenchymal transition (EMT) to drive metastatic dissemination in experimental cancer models. However, tumour cells undergoing EMT have not been observed disseminating into the tissue surrounding human tumour specimens, leaving the relevance to human cancer uncertain. We have previously identified both EpCAM and CD24 as CSC markers that, alongside the mesenchymal marker Vimentin, identify EMT CSCs in human oral cancer cell lines. This afforded the opportunity to investigate whether the combination of these three markers can identify disseminating EMT CSCs in actual human tumours. Examining disseminating tumour cells in over 12,000 imaging fields from 74 human oral tumours, we see a significant enrichment of EpCAM, CD24 and Vimentin co-stained cells disseminating beyond the tumour body in metastatic specimens. Through training an artificial neural network, these predict metastasis with high accuracy (cross-validated accuracy of 87-89%). In this study, we have observed single disseminating EMT CSCs in human oral cancer specimens, and these are highly predictive of metastatic disease.